Drug intelligence / Profile preview

APS001F

Development stage: Phase 2
Lead developer: Anaeropharma Science
Modality: Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Therapies, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Intravenous

Overview

APS001F is an investigational live biotherapeutic product developed by Anaeropharma Science. [1] It consists of a genetically-enhanced strain of the anaerobic bacterium *Bifidobacterium longum*, which is designed to selectively target and kill solid tumors. [1, 2] This novel therapy leverages the hypoxic (low-oxygen) environment characteristic of solid tumor cores, where the intravenously administered APS001F can selectively colonize and proliferate. [1] The bacterium is engineered to express the enzyme cytosine deaminase (CD). [1, 2, 4] This enzyme locally converts a systemically administered, non-toxic prodrug, flucytosine (5-FC), into the potent cytotoxic chemotherapy agent 5-fluorouracil (5-FU) directly at the tumor site. [1, 2, 4] This tumor-specific production of 5-FU aims to achieve high intratumoral concentrations of the anticancer agent while minimizing systemic toxicity associated with conventional chemotherapy. [1, 4]

Other names: CD-expressing bifidobacterium APS001F

Targets

CD (Cluster of Differentiation antigens)

Beyond the preview

Go deeper on APS001F.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APS001F.

Explore the full profile